论文部分内容阅读
[目的]观察硫酸软骨素、西乐葆及莫比可3种药物治疗成人大骨节病的临床疗效,为大骨节病病区患者筛选高效、安全的对症治疗药物提供科学依据。[方法]选择35～60岁有症状的大骨节病患者240人,分为3组,分别给予口服硫酸软骨素、西乐葆及莫比可,根据其治疗前后的WOMAC指数变化情况判断治疗效果。[结果]经过治疗6个月后,硫酸软骨素、西乐葆和莫比可对减轻患者症状及改善关节功能有效率分别为74%、98%和97.5%。[结论]硫酸软骨素治疗成人大骨节病对改善病情有一定的疗效,西乐葆和莫比可对改善大骨节病患者自觉症状及减轻疼痛具有肯定的止痛效果。
[Objective] To observe the curative effect of chondroitin sulfate, celecoxib and moecobill on adult Kashin-Beck disease and to provide a scientific basis for the screening of patients with Kashin-Beck disease efficiently and safely. [Methods] A total of 240 patients with symptoms of Kashin-Beck disease, 35-60 years old, were randomly divided into 3 groups. Oral chondroitin sulfate, celecoxib and mocobactone were given respectively. The therapeutic effect was judged according to the change of WOMAC index before and after treatment. [Result] After 6 months of treatment, the effective rates of chondroitin sulfate, Celebrex and modobile were 74%, 98% and 97.5% respectively for alleviating symptoms and improving joint function. [Conclusion] Chondroitin sulphate treatment of adult Kashin-Beck disease has a certain curative effect on improving the condition. Celebreng and Mobil can have certain analgesic effect on improving the symptoms and relieving pain of patients with Kashin-Beck disease.